公开(公告)号：US11965020B2

公开(公告)日：2024-04-23

申请号：US18318871

申请日：2023-05-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Tong Zhang ,  Erica Pyles ,  Michael Rosconi ,  Nina Liu ,  Supriya Patel ,  Eric Smith ,  Andrew Murphy ,  Chia-Yang Lin ,  Samuel Davis

IPC: C07K16/24 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/244 ,  A61K39/395 ,  A61K47/6845 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

公开(公告)号：US20240102013A1

公开(公告)日：2024-03-28

申请号：US18485592

申请日：2023-10-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Kavita Praveen ,  Giovanni Coppola ,  Manuel Allen Revez Ferreira ,  Lauren Gurski ,  Goncalo Abecasis ,  Aris Baras

IPC: C12N15/113 ,  A61K31/7105 ,  A61K38/46 ,  C12Q1/6816 ,  C12Q1/6883

CPC classification number: C12N15/113 ,  A61K31/7105 ,  A61K38/465 ,  C12Q1/6816 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12Q2600/118

Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.

公开(公告)号：US11937587B2

公开(公告)日：2024-03-26

申请号：US17118241

申请日：2020-12-10

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Kara L. Olson ,  Eric Smith ,  Ka-Man Venus Lai ,  Andrew J. Murphy ,  Gavin Thurston ,  Dayong Guo

IPC: A01K67/027 ,  C07K14/725 ,  C12N5/071 ,  C12N15/85 ,  G01N33/50

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K14/7051 ,  C12N5/0602 ,  C12N15/8509 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0337 ,  Y02A50/30

Abstract: Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.

公开(公告)号：US20240092882A1

公开(公告)日：2024-03-21

申请号：US18462320

申请日：2023-09-06

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Meagan O'BRIEN ,  Gary HERMAN ,  Allen RADIN ,  Michelle DEVEAUX ,  Lorah PERLEE ,  Jamie M. ORENGO

IPC: C07K16/18 ,  A61P37/08

CPC classification number: C07K16/18 ,  A61P37/08 ,  A61K2039/507

Abstract: The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.

公开(公告)号：US11932684B2

公开(公告)日：2024-03-19

申请号：US18117634

申请日：2023-03-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Qian Zhang

IPC: C07K16/16 ,  A61K47/68 ,  G01N30/72 ,  G01N30/80 ,  G01N33/68 ,  H01J49/16

CPC classification number: C07K16/16 ,  A61K47/6803 ,  G01N30/7266 ,  G01N30/80 ,  G01N33/6848 ,  H01J49/165

Abstract: Methods and system for protein characterization using online chromatography and electrospray ionization mass spectrometry are provided.

公开(公告)号：US20240084293A1

公开(公告)日：2024-03-14

申请号：US18502499

申请日：2023-11-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Wen Fury ,  Brian Zambrowicz

IPC: C12N15/10 ,  C12N5/00 ,  C12N5/071 ,  C12N9/22 ,  C12N15/113 ,  G01N21/64 ,  G01N33/68 ,  G16B25/00

CPC classification number: C12N15/1082 ,  C12N5/0018 ,  C12N5/0686 ,  C12N9/22 ,  C12N15/1086 ,  C12N15/1089 ,  C12N15/113 ,  G01N21/6428 ,  G01N33/6896 ,  G16B25/00 ,  A61K48/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

公开(公告)号：US20240083986A1

公开(公告)日：2024-03-14

申请号：US18232238

申请日：2023-08-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jamie M. Orengo ,  Andrew J. Murphy ,  Ashok T. Badithe ,  Vishal Kamat ,  Yashu Liu

IPC: C07K16/16 ,  A61K39/395 ,  A61P37/08

CPC classification number: C07K16/16 ,  A61K39/395 ,  A61P37/08 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.

公开(公告)号：US20240083983A1

公开(公告)日：2024-03-14

申请号：US18453207

申请日：2023-08-21

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Alina BAUM ,  Christos KYRATSOUS

IPC: C07K16/10 ,  C12N15/63

CPC classification number: C07K16/1018 ,  C12N15/63 ,  C07K2317/14 ,  C07K2317/565

Abstract: Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

公开(公告)号：US20240082353A1

公开(公告)日：2024-03-14

申请号：US18452155

申请日：2023-08-18

Applicant: REGENERON PHARMACEUTICALS, INC. ,  SANOFI BIOTECHNOLOGY

Inventor： Jennifer D. HAMILTON ,  Brian N. SWANSON

IPC: A61K38/17 ,  A61K9/00 ,  A61K39/00 ,  A61P17/00 ,  A61P37/08 ,  C07K16/28 ,  G01N33/569

CPC classification number: A61K38/1774 ,  A61K9/0019 ,  A61K39/00 ,  A61P17/00 ,  A61P37/08 ,  C07K16/2866 ,  G01N33/56966 ,  A61K2039/505 ,  A61K2039/545 ,  A61K45/06 ,  C07K2317/76

Abstract: The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

公开(公告)号：US11926670B2

公开(公告)日：2024-03-12

申请号：US17342949

申请日：2021-06-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Daniel B. Dix ,  Xiaolin Tang

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/395 ,  A61K47/18 ,  A61M5/315

CPC classification number: C07K16/2866 ,  A61K9/0019 ,  A61K39/39591 ,  A61K47/183 ,  A61M5/315 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/94

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.